Experimental and Preclinical Imaging

The Experimental and Preclinical Imaging Core provides investigators with the ability to optimize drug treatments, including both small molecule and nanoparticle drug delivery, in small animals and cell lines. The capabilities of the near-infrared and bioluminescence imaging services are compatible with most small animal models. In providing these services it will allow investigators the opportunity for in vivo target validation and dynamic analysis of mechanism of action of novel molecular therapeutics which will advance drug discovery projects more efficiently from bench to bedside. In addition, investigators will learn more about the molecular mechanisms associated with different diseases.

  • Measure drug efficacy by monitoring tumor growth of orthotopic/xenograft models by luminescence or fluorescence
  • X-ray imaging in order to observe development of metastases in intracardiac injection or orthotopic transplantation models
  • Bone Density Software for studying bone diseases, such as arthritis and osteoporosis, and measuring efficacy of drugs and other treatment options that may affect bone mineral and other densities
  • Monitor near IR fluorescent dyes in order to assess drug delivery via nanoparticles
  • Delivery of near IR expression vectors to track gene of interest and/or tumor growth and in vivo target validation of molecular therapies
Sarah Wu
Haworth, room 4002


Biochemistry & Protein Science

Bioinformatics & Modeling


Materials Characterization

Molecular Structures

Translational Biology

Ability to set up 24 NMR experiments at one time and eliminate periodic user intervention
Screen up to 100,000 compounds in two days for endpoint assays
Next-generation genome sequencing
Near-infrared and bioluminescence imaging instrumentation to track gene of interest and/or tumor growth
Expertise in the design and stability of various pharmaceutical dosage forms
More than 40 computational chemistry software programs and databases
KU Today